December 20, 2025 – The Phase III clinical trial results of TenNor Therapeutics’ dual-acting drug, Rifasutenizol (TNP-2198), in a triple regimen as a first-line therapy for Helicobacter pylori infection, which were initially published online in September this year, have now been formally published in the inaugural issue of The Lancet Infectious Diseases 2026.

This Phase III clinical trial was a multicenter, randomized, double-blind, bismuth-containing quadruple therapy-controlled study conducted in China. Led by Professor Zhou Liya from Peking University Third Hospital, the trial covered 40 clinical centers across the country. The results demonstrated that the Rifasutenizol-based triple regimen, as a first-line therapy, exhibited multiple advantages over the current standard bismuth-containing quadruple therapy.

Rifasutenizol is the first new molecular entity specifically developed for Helicobacter pylori since its discovery over 40 years ago. Its multi-target synergistic mechanism is expected to overcome the resistance issues associated with traditional antibiotics, offering new treatment options for patients with Helicobacter pylori infection.

Media Contact:

Phone: +86 512-8686-1986

Email: info@tennorx.com or may.yang@h-advisors.global

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of January 24, 2026, TenNor Therapeutics had built a pipeline of seven innovative programs, including two Core Products, namely, rifasutenizol (TNP-2198), a new molecular entity (“NME”) drug candidate used as part of a triple therapy in combination with amoxicillin and a proton pump inhibitor for the treatment of Helicobacter pylori (“H. pylori”) infection in China and U.S. as well as monotherapy for bacterial vaginosis and C. difficile infection in China; and rifaquizinone (TNP-2092 injection), a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections, i.e. acute bacterial skin and skin structure infection (“ABSSSI”) and prosthetic joint infection (“PJI”), as well as left ventricular assist device infection (“LVADI”) and catheter-related bloodstream infection (“CRBSI”) in China and the U.S.

For more information, please visit: www.tennortherapeutics.com